The treatment of diseases that affect the central nervous system (CNS) represents a great research challenge due to the restriction imposed by the blood-brain barrier (BBB) to allow the passage of drugs into the brain. However, the use of modified nanomedicines engineered with different ligands that can be recognized by receptors expressed in the BBB offers a favorable alternative for this purpose. In this work, a BBB-penetrating peptide, angiopep-2 (Ang-2), was conjugated to poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles through pre- and post-formulation strategies. Then, their ability to cross the BBB was qualitatively assessed on an animal model. Proof-of-concept studies with fluorescent and confocal microscopy studies highlighted that the brain-targeted PLGA nanoparticles were able to cross the BBB and accumulated in neuronal cells, thus showing a promising brain drug delivery system.

PLGA-PEG-ANG-2 Nanoparticles for Blood-Brain Barrier Crossing: Proof-of-Concept Study / Hoyos-Ceballos, Gina P; Ruozi, Barbara; Ottonelli, Ilaria; Da Ros, Federica; Vandelli, Maria Angela; Forni, Flavio; Daini, Eleonora; Vilella, Antonietta; Zoli, Michele; Tosi, Giovanni; Duskey, Jason T; López-Osorio, Betty L. - In: PHARMACEUTICS. - ISSN 1999-4923. - 12:1(2020), pp. 72-83. [10.3390/pharmaceutics12010072]

PLGA-PEG-ANG-2 Nanoparticles for Blood-Brain Barrier Crossing: Proof-of-Concept Study

Ruozi, Barbara;Ottonelli, Ilaria;Da Ros, Federica;Vandelli, Maria Angela;Forni, Flavio;Daini, Eleonora;Vilella, Antonietta;Zoli, Michele;Tosi, Giovanni;Duskey, Jason T
;
2020

Abstract

The treatment of diseases that affect the central nervous system (CNS) represents a great research challenge due to the restriction imposed by the blood-brain barrier (BBB) to allow the passage of drugs into the brain. However, the use of modified nanomedicines engineered with different ligands that can be recognized by receptors expressed in the BBB offers a favorable alternative for this purpose. In this work, a BBB-penetrating peptide, angiopep-2 (Ang-2), was conjugated to poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles through pre- and post-formulation strategies. Then, their ability to cross the BBB was qualitatively assessed on an animal model. Proof-of-concept studies with fluorescent and confocal microscopy studies highlighted that the brain-targeted PLGA nanoparticles were able to cross the BBB and accumulated in neuronal cells, thus showing a promising brain drug delivery system.
2020
12
1
72
83
PLGA-PEG-ANG-2 Nanoparticles for Blood-Brain Barrier Crossing: Proof-of-Concept Study / Hoyos-Ceballos, Gina P; Ruozi, Barbara; Ottonelli, Ilaria; Da Ros, Federica; Vandelli, Maria Angela; Forni, Flavio; Daini, Eleonora; Vilella, Antonietta; Zoli, Michele; Tosi, Giovanni; Duskey, Jason T; López-Osorio, Betty L. - In: PHARMACEUTICS. - ISSN 1999-4923. - 12:1(2020), pp. 72-83. [10.3390/pharmaceutics12010072]
Hoyos-Ceballos, Gina P; Ruozi, Barbara; Ottonelli, Ilaria; Da Ros, Federica; Vandelli, Maria Angela; Forni, Flavio; Daini, Eleonora; Vilella, Antonietta; Zoli, Michele; Tosi, Giovanni; Duskey, Jason T; López-Osorio, Betty L
File in questo prodotto:
File Dimensione Formato  
pharmaceutics-12-00072.pdf

Open access

Descrizione: Articolo principale
Tipologia: Versione pubblicata dall'editore
Dimensione 3.7 MB
Formato Adobe PDF
3.7 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1200615
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 49
  • ???jsp.display-item.citation.isi??? 43
social impact